All In Biotech

Drug Trial Radar · NCT00123916

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial

Last checked: Nov 20, 2026Latest source record: Mar 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,854 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,854

Actual

Start

Nov 2004

Primary completion

Jul 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Population Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR); World Health Organization; Instituto Dante Pazzanese de Cardiologia; University of Sao Paulo
First posted
Jul 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.

Conditions

  • Chagas Disease
  • Trypanosomiasis
  • Heart Disease

Interventions

  • BenznidazoleDrug

    Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)

  • PlaceboDrug

    a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of First of cardiovascular events: Death, Resuscitated Cardiac Arrest, Sustained VentricularTachycardia, New/worsening Heart Failure, New Pacemaker/ICD, Stroke/TIA or other Embolic Events, Cardiac Transplant.Time frame: through study completion, an average of 5 years

Locations

47 sites in 5 countries. Site status is shown where the registry gives one.

  • BENEFIT Investigational Site

    Buenos Aires, Argentina

  • BENEFIT Investigational Site

    Salta, Argentina

  • BENEFIT Ivestigational Site

    Buenos Aires, Apital Federal, Argentina

  • BENEFIT Investigational Site

    Belen de Escobar, Buenos Aires, Argentina

  • BENEFIT Investigational Site

    Isidro Casanova, Buenos Aires, Argentina

  • BENEFIT Investigational Site

    San Juan, Buenos Aires, Argentina

  • BENEFIT Investigational Site

    Santiago Del Estero, Buenos Aires, Argentina

  • BENEFIT Investigational Site

    Santiago Del Estero, Buenos Aires, Argentina

  • BENEFIT Investigational Site

    Buenos Aires, Buenos Aires F.D., Argentina

  • BENEFIT Investigational Site

    Catamarca, Catamarca Province, Argentina

  • BENEFIT Investigational Site

    Charata, Chaco Province, Argentina

  • BENEFIT Investigational Site

    Paraná, Entre Ríos Province, Argentina

  • BENEFIT Investigational Site

    Buenos Aires, General Rodríguez Partido, Argentina

  • BENEFIT Investigational Site

    San Salvador de Jujuy, Jujuy Province, Argentina

  • BENEFIT Investigational Site

    Corrientes, Rosario, Santa Fe, Argentina

  • BENEFIT Investigational Site

    Rosario, Santa Fe Province, Argentina

  • BENEFIT Investigational Site

    Anatuya, Santiago del Estero Province, Argentina

  • BENEFIT Investigational Site

    Santiago del Estero, Sgo. Del Estero, Argentina

  • BENEFIT Investigational Site

    Tupiza, Potosí Department, Bolivia

  • BENEFIT Investigational Site

    Rio de Janeiro, Brazil

  • BENEFIT Investigational Site

    Rio de Janeiro, Brazil

  • BENEFIT Investigational Site

    São Paulo, Brazil

  • BENEFIT Investigational Site

    São Paulo, Brazil

  • BENEFIT Investigational Site

    São Paulo, Brazil

  • BENEFIT Investigational Site

    São Paulo, Brazil

  • BENEFIT Investigational Site

    Salvador, Bahaia, Brazil

  • BENEFIT Investigational Site

    Salvador, Bahaia, Brazil

  • BENEFIT Investigational Site

    Salvador, Bahaia, Brazil

  • BENEFIT Investigational Site

    Carmo, Belo Horizonte, Brazil

  • BENEFIT Investigational Site

    Brasília, Brazilian Federal District, Brazil

  • BENEFIT Investigational Site

    Goiânia, Goiás, Brazil

  • BENEFIT Investigational Site

    Goiânia, Goiás, Brazil

  • BENEFIT Investigational Site

    Goiânia, Goiás, Brazil

  • BENEFIT Investigational Site

    Uberaba, Minas Gerais, Brazil

  • BENEFIT Investigational Site

    Uberlândia, Minas Gerais, Brazil

  • BENEFIT Investigational Site

    Uberlândia, Minas Gerais, Brazil

  • BENEFIT Investigational Site

    Curitiba, Paraná, Brazil

  • BENEFIT Investigational Site

    Recife, Pernambuco, Brazil

  • BENEFIT Investigational Site

    Pelotas, Rio Grande do Sul, Brazil

  • BENEFIT Investigational Site

    Campinas, São Paulo, Brazil

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.